Priority Review Voucher Sales Prices Level Off In 2017
Executive Summary
BioMarin's sale of voucher earned with approval of rare pediatric disease drug Brineura the fourth publicly disclosed voucher sale this year with a price tag between $125m and $150m.
You may also be interested in...
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last
The latest drug development news and highlights from our US FDA Performance Tracker.
Novartis Stockpiling Priority Review Vouchers
Firm picks up second PRV with purchase from Ultragenyx, which is expected to use the $130m to help advance its rare disease development pipeline.